@FierceMedDev: China patent will open Asia's door to Biocept's cancer Dx tests. FierceDiagnostics story | Follow @FierceMedDev
@MichaelGFierce: Purdue team recreates tumor microenvironment to study cancer nanomed delivery. More | Follow @MichaelGFierce
@VarunSaxena2: Treasury's crackdown on inversion could scupper Medtronic-Covidien deal. More | Follow @VarunSaxena2
@EmilyWFierce: Women more likely to skip prenatal testing if they have all the facts at hand, according to new study. More from NPR | Follow @EmilyWFierce
> To consummate their $13 billion merger, orthopedic companies Zimmer ($ZMH) and Biomet are in the midst of a series of integration summits to deal with necessary practical and strategic changes. Story
> The Cleveland Clinic temporarily jumped ship from Apple ($AAPL) to Microsoft ($MSFT). The clinic is using Microsoft's HealthVault to monitor remote or at-risk patients while Apple figures out bugs in its HealthKit platform. More
> Cynosure, a company focused on laser and light-based aesthetic treatments for noninvasive and minimally invasive applications, received FDA clearance to market its PicoSure device to treat wrinkles. It's already FDA-cleared for tattoo and benign pigmented lesion removal. Release
> Therapeutic device company Aethlon Medical announced a partnership with Qualtran to expand human clinical studies of Hemopurifier therapy to include patients suffering from dengue virus. Release
Biotech News
@FierceBiotech: Lipocine's low-T drug hits the mark in Phase III. Now it has to sway the FDA. Article | Follow @FierceBiotech
@JohnCFierce: Ahead of a split, Baxter strikes a $970M deal for Merrimack's lead cancer drug. News | Follow @JohnCFierce
@DamianFierce: But how will the $MACK deal affect the coming biotech softball playoffs? More from The Boston Globe | Follow @DamianFierce
> Waksal's back: Once-jailed biotech chief plots an IPO for his latest play. News
> Novartis-partnered Eureka rounds up $21M round for immuno-oncology drug research. Story
> Gilead heads to FDA after wrapping a PhIII HIV combo drug program. Item
> Bristol-Myers plots a 2,500-worker campus in New Jersey. Article
Pharma News
@FiercePharma: Man gets 25 years for violent last-mile robberies. FiercePharmaManufacturing story | Follow @FiercePharma
@EricPFierce: Mylan proposes plan to avoid nitroglycerin shortage in Canada. More from FiercePharmaManufacturing | Follow @EricPFierce
> GlaxoSmithKline soon to name RBS chair Hampton as next chairman. Report
> Oh, what a tangled web of pharma M&A, starring Pfizer, Actavis, Allergan and Salix. Story
> Ackman threatens Allergan with lawsuit if Salix deal is sealed. Article
Drug Delivery News
> FDA moves aggressively on low-T drugs, but replacement pill still aims to enter market. Item
> Purdue team recreates tumor microenvironment to study cancer nanomed delivery. Report
> Novaliq's cyclosporin drop for dry eyes boasts PhI success. Story
> Titan Pharma trial of implant for addicts on track. Article
> English researchers fuse biologics to antibodies to treat rheumatoid arthritis. More
Diagnostics News
> NuView, Otsuka Pharmaceutical establish cancer biomarker licensing deal. News
> ImaginAb envisions in vivo molecular imaging tech as treatment assessment tool. Report
> Sequenom keeps prenatal Dx competition running with new positive data. Article
> T2 Biosystems gains FDA signoff for time-saving Candida Dx. Story
> U.K., Italy team push for regular Dx testing of prostate cancer patients under treatment. More
Pharma Marketing News
> Celgene's Otezla nabs psoriasis approval, launching next-gen showdown. Report
> J&J 'disappointed' U.K. watchdogs nixed Olysio-Sovaldi hep C combo. What next? More
> CNBC: Actavis swoops in on Allergan for Salix buyout talks. Item
> Can copay coupons be kickbacks? HHS says yes. More
> Bayer goes Glamour-ous with Girls star for new IUD campaign. Article